6.83
전일 마감가:
$6.73
열려 있는:
$6.64
하루 거래량:
1.01M
Relative Volume:
1.29
시가총액:
$368.68M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-4.3228
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-12.55%
1개월 성능:
-0.15%
6개월 성능:
+72.47%
1년 성능:
-24.20%
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
FULC
Fulcrum Therapeutics Inc
|
6.83 | 363.28M | 2.81M | -97.34M | -91.47M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
2023-09-25 | 개시 | Goldman | Neutral |
2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-11-15 | 개시 | Goldman | Buy |
2022-03-08 | 개시 | Oppenheimer | Outperform |
2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-03-22 | 개시 | Credit Suisse | Outperform |
2021-03-02 | 개시 | Stifel | Buy |
2020-10-16 | 개시 | Piper Sandler | Overweight |
2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2020-08-12 | 재확인 | H.C. Wainwright | Buy |
2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2020-06-17 | 개시 | BTIG Research | Buy |
2019-10-03 | 개시 | H.C. Wainwright | Buy |
2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
When is Fulcrum Therapeutics Inc. stock expected to show significant growthFree Market Dynamics Reports - jammulinksnews.com
How strong is Fulcrum Therapeutics Inc. company’s balance sheetMaximize returns with timely market signals - jammulinksnews.com
How does Fulcrum Therapeutics Inc. generate profit in a changing economyHigh-profit capital plays - jammulinksnews.com
What institutional investors are buying Fulcrum Therapeutics Inc. stockInvest smarter with cutting-edge analytics - jammulinksnews.com
Is Fulcrum Therapeutics Inc. stock overvalued or undervaluedAccess exclusive market insights for free - jammulinksnews.com
What is Fulcrum Therapeutics Inc. company’s growth strategyPre Market Forecasts For Smart Trading - jammulinksnews.com
FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald - Defense World
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningTrend Confirmation Scanner with Entry Focus - Newser
Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsOversold Opportunity Scanner with RSI Data - Newser
Q3 Earnings Forecast for FULC Issued By Leerink Partnrs - Defense World
Is Fulcrum Therapeutics Inc. stock ready for a breakoutReal-Time AI Entry Forecast Generator - Newser
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Portfolio Diversification Stock Ideas - Newser
Are Bears Losing Grip on Fulcrum Therapeutics Inc.Reliable Investment Entry Signals Confirmed by Charts - metal.it
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Multi-Year Signal Summary and Entry Timing - Newser
What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Market Forecast Tracker For Smart Trading - jammulinksnews.com
How to interpret RSI for Fulcrum Therapeutics Inc. stockTen-Year Sector Performance and Summary Analysis - Newser
What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockPre Market Insights For Beginners - jammulinksnews.com
How many analysts rate Fulcrum Therapeutics Inc. as a “Buy”Wealth Building Picks That Work - jammulinksnews.com
Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.29 Consensus Target Price from Brokerages - Defense World
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsAI Trading Suggestions With Accuracy Focus Released - metal.it
Fulcrum Therapeutics stock price target raised to $5 at RBC Capital - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Buy at HC Wainwright - Defense World
Is Fulcrum Therapeutics Inc. building a consolidation baseTrend Following Ideas with Volume Confirmation - Newser
Published on: 2025-07-30 02:00:45 - Newser
Fulcrum Therapeutics 2024 Q2 Earnings Strong Turnaround with Net Income Swing of 333% - AInvest
Fulcrum defended at H.C. Wainwright post sickle cell disease data - Seeking Alpha
H.C. Wainwright upgrades Fulcrum Therapeutics stock rating on promising SCD data - Investing.com Canada
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease Treatment - TipRanks
HC Wainwright Raises Fulcrum Therapeutics' PT to $12 from $4 - AInvest
Fulcrum Therapeutics Inc. Stock Fails to Break Resistance Traders ReactDaily Smart Money Movement Monitor Activated - beatles.ru
Fulcrum Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fulcrum Therapeutics, Inc. SEC 10-Q Report - TradingView
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Fulcrum Therapeutics Plunges 29.58% on PIONEER Trial Results - AInvest
Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 1c - StreetInsider
Fulcrum Therapeutics stock falls after sickle cell disease trial results By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics stock falls after sickle cell disease trial results - Investing.com
Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics Reports Positive Results from Phase 1b PIONEER Trial of Pociredir for Sickle Cell Disease - Quiver Quantitative
Fulcrum Therapeutics reports Q2 results, pociredir trial data - StreetInsider
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - Yahoo Finance
Breakthrough Sickle Cell Treatment Achieves 44% Success Rate in Latest Clinical Trial Data - Stock Titan
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionDaily Investment Ideas with Market Insight - Newser
Published on: 2025-07-29 13:21:15 - beatles.ru
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicalsDaily Stock Watch Summary with Key Insights - Newser
Fulcrum Therapeutics Soars 16.52% on Sickle Cell Trial Hype - AInvest
Momentum Screeners Rank Fulcrum Therapeutics Inc. in Top 5 TodayWeekly Top Gainers Forecast Watchlist Released - beatles.ru
Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):